NI201100093A - 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6. - Google Patents

1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6.

Info

Publication number
NI201100093A
NI201100093A NI201100093A NI201100093A NI201100093A NI 201100093 A NI201100093 A NI 201100093A NI 201100093 A NI201100093 A NI 201100093A NI 201100093 A NI201100093 A NI 201100093A NI 201100093 A NI201100093 A NI 201100093A
Authority
NI
Nicaragua
Prior art keywords
piperazin
hydroxitriptamine
arilsulfonil
benzimidazoles
binders
Prior art date
Application number
NI201100093A
Other languages
English (en)
Spanish (es)
Inventor
M Andrae Patrick
N Haydar Simon
J Robichaud Albert
Yun Heedong
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100093(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of NI201100093A publication Critical patent/NI201100093A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NI201100093A 2008-11-11 2011-05-10 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6. NI201100093A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
NI201100093A true NI201100093A (es) 2011-10-31

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100093A NI201100093A (es) 2008-11-11 2011-05-10 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6.

Country Status (41)

Country Link
US (1) US8063053B2 (en:Method)
EP (1) EP2285784B1 (en:Method)
JP (1) JP5087171B2 (en:Method)
KR (1) KR101323417B1 (en:Method)
CN (1) CN102209713B (en:Method)
AP (1) AP2814A (en:Method)
AR (1) AR074325A1 (en:Method)
AU (1) AU2009314221B2 (en:Method)
BR (1) BRPI0920682A2 (en:Method)
CA (1) CA2740262C (en:Method)
CL (1) CL2011001050A1 (en:Method)
CO (1) CO6440548A2 (en:Method)
CR (1) CR20110247A (en:Method)
CU (1) CU24020B1 (en:Method)
CY (1) CY1113025T1 (en:Method)
DK (1) DK2285784T3 (en:Method)
DO (1) DOP2011000130A (en:Method)
EA (1) EA018369B1 (en:Method)
EC (1) ECSP11011045A (en:Method)
ES (1) ES2389694T3 (en:Method)
GE (1) GEP20135805B (en:Method)
HR (1) HRP20120561T1 (en:Method)
IL (1) IL212213A0 (en:Method)
MA (1) MA32788B1 (en:Method)
ME (1) ME01129B (en:Method)
MX (1) MX2011004996A (en:Method)
MY (1) MY156324A (en:Method)
NI (1) NI201100093A (en:Method)
NZ (1) NZ592563A (en:Method)
PE (1) PE20120026A1 (en:Method)
PL (1) PL2285784T3 (en:Method)
PT (1) PT2285784E (en:Method)
RS (1) RS52381B (en:Method)
SA (1) SA109300673B1 (en:Method)
SI (1) SI2285784T1 (en:Method)
SV (1) SV2011003902A (en:Method)
TN (1) TN2011000203A1 (en:Method)
TW (1) TWI481605B (en:Method)
UA (1) UA100192C2 (en:Method)
WO (1) WO2010056644A1 (en:Method)
ZA (1) ZA201103283B (en:Method)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804792A1 (en) * 2004-09-20 2007-07-11 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
CA2580857A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286648A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
EP4121413A4 (en) * 2020-04-22 2024-04-17 Recurium IP Holdings, LLC PREPARATION OF A SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENT

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
WO1999002502A2 (en) 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
ES2192394T3 (es) 1998-08-10 2003-10-01 Winston Pharmateuticals Llc Profarmacos de inhibidores de la bomba de protones.
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
CA2422717A1 (en) 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
PL213134B1 (pl) * 2000-11-02 2013-01-31 Wyeth Corp 1-arylo- lub 1-alkilosulfonylo- heterocyklilobenzazole, ich zastosowanie oraz kompozycja farmaceutyczna zawierajaca te zwiazki
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CA2450245A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
US7745436B2 (en) 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
EP1778242A4 (en) 2004-07-28 2010-10-20 Irm Llc COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDHORMONE NUCLEAR RECEPTORS
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
ES2389694T3 (es) 2012-10-30
JP2012508275A (ja) 2012-04-05
AU2009314221B2 (en) 2012-08-30
AU2009314221A1 (en) 2010-05-20
PE20120026A1 (es) 2012-02-12
DOP2011000130A (es) 2017-04-30
CY1113025T1 (el) 2016-04-13
NZ592563A (en) 2012-10-26
MY156324A (en) 2016-02-15
EP2285784A1 (en) 2011-02-23
TN2011000203A1 (fr) 2012-12-17
CN102209713A (zh) 2011-10-05
EA201100696A1 (ru) 2011-10-31
TW201022247A (en) 2010-06-16
TWI481605B (zh) 2015-04-21
CA2740262C (en) 2013-05-28
HRP20120561T1 (hr) 2012-07-31
AR074325A1 (es) 2011-01-05
ZA201103283B (en) 2012-01-25
CL2011001050A1 (es) 2011-08-19
IL212213A0 (en) 2011-06-30
PL2285784T3 (pl) 2012-12-31
MX2011004996A (es) 2011-05-25
ECSP11011045A (es) 2011-06-30
GEP20135805B (en) 2013-04-10
US8063053B2 (en) 2011-11-22
JP5087171B2 (ja) 2012-11-28
SA109300673B1 (ar) 2013-05-25
EP2285784B1 (en) 2012-07-04
AP2814A (en) 2013-12-31
DK2285784T3 (da) 2012-07-23
CA2740262A1 (en) 2010-05-20
MA32788B1 (fr) 2011-11-01
PT2285784E (pt) 2012-09-19
ME01129B (me) 2013-03-20
RS52381B (sr) 2012-12-31
WO2010056644A8 (en) 2010-11-18
HK1158647A1 (en) 2012-07-20
SV2011003902A (es) 2011-07-05
US20100120779A1 (en) 2010-05-13
BRPI0920682A2 (pt) 2016-09-27
UA100192C2 (en) 2012-11-26
CO6440548A2 (es) 2012-05-15
AP2011005664A0 (en) 2011-04-30
EA018369B1 (ru) 2013-07-30
SI2285784T1 (sl) 2012-08-31
KR20110075013A (ko) 2011-07-05
CN102209713B (zh) 2014-07-02
CU24020B1 (es) 2014-07-30
CU20110101A7 (es) 2012-01-31
KR101323417B1 (ko) 2013-10-29
WO2010056644A1 (en) 2010-05-20
CR20110247A (es) 2011-06-24

Similar Documents

Publication Publication Date Title
NI201100093A (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6.
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
CU20110052A7 (es) Compuestos orgánicos
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
NZ600210A (en) Substituted 4-aminocyclohexane derivatives
CR11727A (es) Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina
CY1114764T1 (el) Παραγωγα προλινης ως αναστολεις καθεψινης
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
EA201200018A1 (ru) Триазольные соединения, несущие серосодержащий заместитель
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
EA201200741A1 (ru) Способ получения этексилата дабигатрана
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
EA201170282A1 (ru) Фунгицидные n-циколоалкил-n-бифенилметилкарбоксамидные производные
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY30534A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii
NI201100035A (es) Agentes antifúngicos.
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
ATE481395T1 (de) Cyclohexylderivate
CR10678A (es) Nuevos derivados de acidos vinilogos ii
CU23681B7 (es) Derivados de triazolopirazina
ECSP11010817A (es) Agentes antifúngicos